# Nanjing TransThera Biosciences Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanjing-transthera-biosciences-co

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.transtherabio.com
- Total disclosed funding: $258M
- Latest round: Series D (Feb 20, 2023)
- Investors on record: 24

## About

Based in Nanjing, China, and founded in 2016, Nanjing TransThera Biosciences Co. Ltd. specializes in the treatment of oncology, cardiovascular, and inflammatory diseases. The company was founded by Frank Wu. In July 2021, Nanjing TransThera Biosciences Co. Ltd. raised USD 100 million in Series D funding co-led by new investors CCT Fund Management and CPE Funds Management, with participation from other new investors. In 2020, the company has cooperated with Teijin Polycarbonate.

Nanjing TransThera Biosciences Co. Ltd. is a biotechnology company specializing in developing therapeutics for diseases that need major treatment, like oncology, cardiovascular, and inflammatory diseases. The company's advanced pipeline product, IT-00420, is a clinical-stage spectrum-selective kinase inhibitor that exerts anti-tumor effects by targeting tumor cells and improving the tumor microenvironment. The company's other products include IT-00434 for gastrointestinal tumors, IT-01688 for IBD, TT-00920 for heart failure, and TT-01025 for non-alcoholic steatohepatitis (NASH).

The company plans to provide better options for GI cancer patients through collaboration with Roche in the future.

## Funding rounds

- Series D, Feb 20, 2023, $38M — BOCGI Zheshang Capital, Shanghai Guoxin Venture Capital Investment, Jinkong Qiyuan Capital, Nanjing Dajiangbei Guozi Investment Group, Xuantong Venture Capital, Honest Capital, Trinity Innovation Fund, Qilan Asset Management
- Series D, Jul 25, 2021, $100M — CPE Funds Management, GP Capital, China Merchants Capital, CoStone Capital, CCT Fund Management, Winfast Holding, Sixty Degree Capital
- Series C, Feb 9, 2021, $50M — China Merchants Capital, Co-Stone Capital, SDIC Venture Capital, Fengling Capital
- Series C, Jul 22, 2020, $60M — GP Capital, Grand Yangtze Capital, SDIC Venture Capital, Oceanpine Capital, Ennovation Ventures, CMG-SDIC Capital Management
- Series A, Apr 14, 2020 — CS Capital
- Series A, Dec 6, 2016, $10M — 5Y Capital, Grand Yangtze Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- Grand Yangtze Capital (https://capitalatlas.ai/funds/grand-yangtze-capital) — Series A, Series C
- CS Capital — Series A
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series C, Series D
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series C
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series C
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series C
- CMG-SDIC Capital Management — Series C
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series C, Series D
- Co-Stone Capital — Series C
- Fengling Capital — Series C
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series D
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series D
- CCT Fund Management — Series D
- Winfast Holding (https://capitalatlas.ai/funds/winfast-holding) — Series D
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series D
- BOCGI Zheshang Capital (https://capitalatlas.ai/funds/bocgi-zheshang-capital) — Series D
- Shanghai Guoxin Venture Capital Investment — Series D
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series D
- Nanjing Dajiangbei Guozi Investment Group — Series D
- Xuantong Venture Capital (https://capitalatlas.ai/funds/xuantong-venture-capital) — Series D
- Honest Capital (https://capitalatlas.ai/funds/honest-capital) — Series D
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series D
- Qilan Asset Management — Series D